[{"id":"7a52caf1-0dfe-4289-a790-01f8d7b2993f","acronym":"DUAL-CAR-NK-GB","url":"https://clinicaltrials.gov/study/NCT07480941","created_at":"2026-03-28T01:39:30.783Z","updated_at":"2026-03-28T01:39:30.783Z","phase":"Phase 1","brief_title":"Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma","source_id_and_acronym":"NCT07480941 - DUAL-CAR-NK-GB","lead_sponsor":"Beijing Biotech","biomarkers":" EGFR • CD276 • IL13RA2","pipe":" | ","alterations":" EGFR wild-type","tags":["EGFR • CD276 • IL13RA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 02/02/2026","start_date":" 02/02/2026","primary_txt":" Primary completion: 02/18/2027","primary_completion_date":" 02/18/2027","study_txt":" Completion: 03/17/2028","study_completion_date":" 03/17/2028","last_update_posted":"2026-03-18"},{"id":"ef9e7260-d9e3-483f-aa0a-3b74c6c79ebc","acronym":"VANGUARD","url":"https://clinicaltrials.gov/study/NCT07469735","created_at":"2026-03-28T01:44:12.900Z","updated_at":"2026-03-28T01:44:12.900Z","phase":"","brief_title":"Vorasidenib Guided by AGX PET in Recurrent/Low-grade Glioma","source_id_and_acronym":"NCT07469735 - VANGUARD","lead_sponsor":"Huashan Hospital","biomarkers":" IDH1 • IDH2","pipe":"","alterations":" ","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Voranigo (vorasidenib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 04/01/2026","start_date":" 04/01/2026","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2026-03-13"},{"id":"c31fe31a-3823-4e8c-81cc-892c70bccfed","acronym":"","url":"https://clinicaltrials.gov/study/NCT07206849","created_at":"2025-10-11T01:31:02.610Z","updated_at":"2025-10-11T01:31:02.610Z","phase":"Phase 2","brief_title":"Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)","source_id_and_acronym":"NCT07206849","lead_sponsor":"Nationwide Children's Hospital","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ojemda (tovorafenib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 79","initiation":"Initiation: 03/01/2026","start_date":" 03/01/2026","primary_txt":" Primary completion: 03/01/2030","primary_completion_date":" 03/01/2030","study_txt":" Completion: 03/01/2037","study_completion_date":" 03/01/2037","last_update_posted":"2025-10-03"},{"id":"3ba5c955-8ec9-4668-a6f6-e10f2a3b745e","acronym":"","url":"https://clinicaltrials.gov/study/NCT07004075","created_at":"2025-06-07T14:43:33.080Z","updated_at":"2025-06-07T14:43:33.080Z","phase":"Phase 3","brief_title":"FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration","source_id_and_acronym":"NCT07004075","lead_sponsor":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • temozolomide • Ivesa (firmonertinib) • Fu Mai Ning (luvometinib) • vindesine"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 102","initiation":"Initiation: 06/30/2025","start_date":" 06/30/2025","primary_txt":" Primary completion: 04/30/2027","primary_completion_date":" 04/30/2027","study_txt":" Completion: 04/30/2029","study_completion_date":" 04/30/2029","last_update_posted":"2025-06-04"},{"id":"06a32910-5164-4ca7-97f9-f7590ef316a6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03605550","created_at":"2023-02-21T22:01:39.413Z","updated_at":"2025-02-25T12:26:57.526Z","phase":"Phase 1","brief_title":"A Phase 1b Study of PTC596 in Children with Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma","source_id_and_acronym":"NCT03605550","lead_sponsor":"Nationwide Children's Hospital","biomarkers":" BMI1","pipe":"","alterations":" ","tags":["BMI1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e unesbulin (BMIi-1)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 08/01/2018","start_date":" 08/01/2018","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 03/01/2029","study_completion_date":" 03/01/2029","last_update_posted":"2025-02-24"},{"id":"26646272-f3f1-4cb9-84dd-16ded62b0796","acronym":"","url":"https://clinicaltrials.gov/study/NCT01875601","created_at":"2021-01-29T07:04:49.340Z","updated_at":"2025-02-25T12:36:34.409Z","phase":"Phase 1","brief_title":"NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors","source_id_and_acronym":"NCT01875601","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • rhIL-15"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 06/11/2013","start_date":" 06/11/2013","primary_txt":" Primary completion: 09/08/2015","primary_completion_date":" 09/08/2015","study_txt":" Completion: 09/08/2015","study_completion_date":" 09/08/2015","last_update_posted":"2025-02-24"},{"id":"3b32d8a5-c5ea-4195-a505-ea0c6246c9c2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04119024","created_at":"2021-01-18T20:07:53.813Z","updated_at":"2025-02-25T12:27:21.879Z","phase":"Phase 1","brief_title":"Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors","source_id_and_acronym":"NCT04119024","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Imunace (teceleukin) • MB-101 • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 11/27/2019","start_date":" 11/27/2019","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2025-02-24"},{"id":"6d19b3f0-4cc5-4aec-9cc7-a1e6cef5690a","acronym":"","url":"https://clinicaltrials.gov/study/NCT00924196","created_at":"2021-01-18T03:34:45.955Z","updated_at":"2025-02-25T12:25:33.732Z","phase":"","brief_title":"Natural History Study of Patients With Neurofibromatosis Type I","source_id_and_acronym":"NCT00924196","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NF1","pipe":" | ","alterations":" NF1 mutation","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF1 mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 259","initiation":"Initiation: 02/25/2008","start_date":" 02/25/2008","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2025-02-24"},{"id":"8a5aaf87-2ebe-47a9-9059-1dd07561e78b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05555550","created_at":"2022-09-27T14:04:30.866Z","updated_at":"2025-02-25T12:29:00.965Z","phase":"Phase 1","brief_title":"Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG","source_id_and_acronym":"NCT05555550","lead_sponsor":"Children's Hospital of Philadelphia","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/03/2025","start_date":" 03/03/2025","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2025-02-24"},{"id":"b75ecd93-1120-4cfc-9f9a-b68e1481f48d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05588141","created_at":"2022-10-20T14:11:44.038Z","updated_at":"2025-02-25T12:29:09.098Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations","source_id_and_acronym":"NCT05588141","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zotiraciclib (TG02)"],"overall_status":"Recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 05/16/2023","start_date":" 05/16/2023","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/02/2029","study_completion_date":" 08/02/2029","last_update_posted":"2025-02-24"},{"id":"bf5cc737-c6cb-4899-99a5-c61a24a807ae","acronym":"SJ901","url":"https://clinicaltrials.gov/study/NCT04923126","created_at":"2021-06-11T18:56:10.986Z","updated_at":"2025-02-25T12:37:53.246Z","phase":"Phase 1/2","brief_title":"SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma","source_id_and_acronym":"NCT04923126 - SJ901","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" BRAF • NF1 • PTPN11 • MYBL1","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF • NF1 • PTPN11 • MYBL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gomekli (mirdametinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 132","initiation":"Initiation: 06/21/2021","start_date":" 06/21/2021","primary_txt":" Primary completion: 06/01/2031","primary_completion_date":" 06/01/2031","study_txt":" Completion: 06/01/2031","study_completion_date":" 06/01/2031","last_update_posted":"2025-02-24"},{"id":"1e4b972b-a78c-437b-a2e3-d4f2e74d347d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03952598","created_at":"2021-01-18T19:27:16.826Z","updated_at":"2025-02-25T13:39:51.583Z","phase":"Phase 2","brief_title":"Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy","source_id_and_acronym":"NCT03952598","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 270","initiation":"Initiation: 10/16/2019","start_date":" 10/16/2019","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-21"},{"id":"42d928bf-01a8-4f38-bc3e-dbcbf7fa205e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06161974","created_at":"2023-12-08T22:16:35.701Z","updated_at":"2025-02-25T13:41:56.353Z","phase":"Phase 2","brief_title":"Study of Olutasidenib and Temozolomide in HGG","source_id_and_acronym":"NCT06161974","lead_sponsor":"Rigel Pharmaceuticals","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 mutation","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Rezlidhia (olutasidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 03/01/2025","start_date":" 03/01/2025","primary_txt":" Primary completion: 06/01/2029","primary_completion_date":" 06/01/2029","study_txt":" Completion: 06/01/2035","study_completion_date":" 06/01/2035","last_update_posted":"2025-02-21"},{"id":"6076406a-9463-43ad-ba76-13f9a5a2bd1c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01445288","created_at":"2021-01-18T05:59:39.581Z","updated_at":"2025-02-25T13:39:05.076Z","phase":"","brief_title":"Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors","source_id_and_acronym":"NCT01445288","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" VEGFA • TNFA","pipe":"","alterations":" ","tags":["VEGFA • TNFA"],"overall_status":"Completed","enrollment":" Enrollment 76","initiation":"Initiation: 12/05/2006","start_date":" 12/05/2006","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2025-02-21"},{"id":"2d273f1a-d076-4196-b160-67a7c935aa6c","acronym":"NCI-2014-01488","url":"https://clinicaltrials.gov/study/NCT02208362","created_at":"2021-03-16T19:52:14.281Z","updated_at":"2025-02-25T14:06:49.902Z","phase":"Phase 1","brief_title":"Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma","source_id_and_acronym":"NCT02208362 - NCI-2014-01488","lead_sponsor":"City of Hope Medical Center","biomarkers":" IL13RA2","pipe":" | ","alterations":" CD123 expression","tags":["IL13RA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MB-101"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 05/18/2015","start_date":" 05/18/2015","primary_txt":" Primary completion: 02/08/2021","primary_completion_date":" 02/08/2021","study_txt":" Completion: 07/08/2025","study_completion_date":" 07/08/2025","last_update_posted":"2025-02-19"},{"id":"3c5d0961-29c6-44c5-9f18-012dc3b4ae3e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06504381","created_at":"2025-02-25T14:04:35.935Z","updated_at":"2025-02-25T14:04:35.935Z","phase":"Phase 1/2","brief_title":"DB107-RRV, DB107-FC, and Radiation Therapy with or Without Temozolomide (TMZ) for High Grade Glioma","source_id_and_acronym":"NCT06504381","lead_sponsor":"University of California, San Francisco","biomarkers":" MGMT","pipe":"","alterations":" ","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • vocimagene amiretrorepvec/extended release flucytosine (DB107)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 01/08/2025","start_date":" 01/08/2025","primary_txt":" Primary completion: 01/31/2028","primary_completion_date":" 01/31/2028","study_txt":" Completion: 01/31/2042","study_completion_date":" 01/31/2042","last_update_posted":"2025-02-19"},{"id":"70012bdf-9a68-4791-98f7-f3a645c2ba06","acronym":"","url":"https://clinicaltrials.gov/study/NCT04295759","created_at":"2021-01-18T20:50:32.592Z","updated_at":"2025-02-25T14:01:55.137Z","phase":"Phase 1","brief_title":"INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas","source_id_and_acronym":"NCT04295759","lead_sponsor":"Pediatric Brain Tumor Consortium","biomarkers":" HER-2 • CD4 • ADAM10","pipe":"","alterations":" ","tags":["HER-2 • CD4 • ADAM10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e aderbasib (INCB7839)"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 07/27/2020","start_date":" 07/27/2020","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2025-02-19"},{"id":"204cae00-5d2c-422e-af6c-ba51e68ea377","acronym":"CONNECT1903","url":"https://clinicaltrials.gov/study/NCT04655404","created_at":"2021-01-19T20:41:28.986Z","updated_at":"2025-02-25T14:15:44.274Z","phase":"Phase 1","brief_title":"A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma with NTRK Fusion","source_id_and_acronym":"NCT04655404 - CONNECT1903","lead_sponsor":"Nationwide Children's Hospital","biomarkers":" NTRK","pipe":" | ","alterations":" NTRK fusion","tags":["NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vitrakvi (larotrectinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 04/08/2021","start_date":" 04/08/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-18"},{"id":"b568f31d-6b2b-46ca-879f-a90916765687","acronym":"","url":"https://clinicaltrials.gov/study/NCT05099003","created_at":"2021-10-29T14:53:11.674Z","updated_at":"2025-02-25T14:08:27.717Z","phase":"Phase 1/2","brief_title":"A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)","source_id_and_acronym":"NCT05099003","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF • IDH1","pipe":" | ","alterations":" BRAF mutation • BRAF V600 • IDH1 mutation","tags":["BRAF • IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600 • IDH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xpovio (selinexor)"],"overall_status":"Suspended","enrollment":" Enrollment 210","initiation":"Initiation: 05/31/2022","start_date":" 05/31/2022","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-02-18"},{"id":"b727510f-e4dd-45d1-a75b-a7fd6215444a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03598244","created_at":"2021-01-18T17:41:26.385Z","updated_at":"2025-02-25T14:15:11.442Z","phase":"Phase 1","brief_title":"Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors","source_id_and_acronym":"NCT03598244","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MET","pipe":" | ","alterations":" MET amplification","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Orpathys (savolitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 11/27/2018","start_date":" 11/27/2018","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2025-02-18"},{"id":"09faeec2-6d19-4e99-bfa8-ce9ad5372038","acronym":"","url":"https://clinicaltrials.gov/study/NCT05843253","created_at":"2023-05-06T15:04:11.203Z","updated_at":"2025-02-25T14:09:40.595Z","phase":"Phase 2","brief_title":"Study of Ribociclib and Everolimus in HGG and DIPG","source_id_and_acronym":"NCT05843253","lead_sponsor":"Nationwide Children's Hospital","biomarkers":" PIK3CA • PTEN • CDKN2A • RB1 • CCND1 • CDK4 • CDKN2B • PIK3R1 • CDK6 • CCND2 • CDKN2C","pipe":" | ","alterations":" PIK3CA mutation • CDKN2A deletion","tags":["PIK3CA • PTEN • CDKN2A • RB1 • CCND1 • CDK4 • CDKN2B • PIK3R1 • CDK6 • CCND2 • CDKN2C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • CDKN2A deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Kisqali (ribociclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 08/22/2024","start_date":" 08/22/2024","primary_txt":" Primary completion: 08/28/2028","primary_completion_date":" 08/28/2028","study_txt":" Completion: 08/28/2034","study_completion_date":" 08/28/2034","last_update_posted":"2025-02-17"},{"id":"64ec7fee-f0ad-4556-bc3c-857c74e02812","acronym":"","url":"https://clinicaltrials.gov/study/NCT04145115","created_at":"2021-07-05T17:26:08.613Z","updated_at":"2025-02-25T14:07:33.392Z","phase":"Phase 2","brief_title":"A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden","source_id_and_acronym":"NCT04145115","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • TP53 • CDKN2A • TERT • CDKN2B • ATRX","pipe":" | ","alterations":" TP53 mutation • EGFR mutation • EGFR amplification • CDKN2A deletion • IDH wild-type","tags":["EGFR • TP53 • CDKN2A • TERT • CDKN2B • ATRX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • EGFR mutation • EGFR amplification • CDKN2A deletion • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar)"],"overall_status":"Suspended","enrollment":" Enrollment 37","initiation":"Initiation: 12/24/2020","start_date":" 12/24/2020","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 05/31/2025","study_completion_date":" 05/31/2025","last_update_posted":"2025-02-17"},{"id":"74915413-c151-4ff8-ac18-adfbd918fb7c","acronym":"","url":"https://clinicaltrials.gov/study/NCT06000787","created_at":"2023-08-21T15:09:02.705Z","updated_at":"2025-02-25T14:09:59.668Z","phase":"","brief_title":"MCT for the Harvard/UCSF ROBIN Center","source_id_and_acronym":"NCT06000787","lead_sponsor":"Brigham and Women's Hospital","biomarkers":" MYCN","pipe":" | ","alterations":" MYCN amplification","tags":["MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Azedra (iobenguane I 131)"],"overall_status":"Recruiting","enrollment":" Enrollment 47","initiation":"Initiation: 09/19/2023","start_date":" 09/19/2023","primary_txt":" Primary completion: 08/31/2028","primary_completion_date":" 08/31/2028","study_txt":" Completion: 08/31/2028","study_completion_date":" 08/31/2028","last_update_posted":"2025-02-17"},{"id":"22e86fd8-4f8f-4456-992c-88f257edf9a4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05345002","created_at":"2022-04-25T21:58:14.873Z","updated_at":"2025-02-25T14:41:19.773Z","phase":"Phase 2","brief_title":"All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma","source_id_and_acronym":"NCT05345002","lead_sponsor":"Stephen Bagley, MD, MSCE","biomarkers":" IDH1 • IDH2 • MGMT","pipe":" | ","alterations":" IDH1 mutation • IDH2 mutation","tags":["IDH1 • IDH2 • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zynyz (retifanlimab-dlwr)"],"overall_status":"Recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 11/16/2022","start_date":" 11/16/2022","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-02-14"}]